Pharma News, 2022

The European Union has approved AstraZeneca’s lupus drug Saphnelo (anifrolumab), a first-in-class type 1 interferon receptor antibody as an add-on therapy for the treatment of severe, active aut...

Robert Califf, MD, received Senate approval today to become FDA commissioner in a 50-46 vote, in which 6 Republicans supported him and 5 Democrats voted against his confirmation.

The European Medicines Agency (EMA) safety committee has begun a safety review of Janus kinase (JAK) inhibitors made by Pfizer, AbbVie, Eli Lilly and Belgian biotech Galapagos for the treatment of...

GlaxoSmithKline (GSK) has become the 14th drugmaker to limit its involvement in the 340B Drug Discount Program.

The US Food and Drug Administration (FDA) has granted a Fast-Track Designation to Axcella Therapeutics’ AXA1125 to treat non-alcoholic steatohepatitis (NASH) with liver fibrosis. ...

Continuous Glucose Monitoring System Manufacturer Sensonics has received FDA approval for its Eversense E3, which can be used to measure glucose levels in adults with diabetes for up to six months....

Pfizer and Biohaven said a single 75-mg dose of their experimental migraine drug, rimegepant, significantly reduced acute symptoms starting at two hours and lasting for up to 48 hours. ...

In a rare moment of solidarity among fierce competitors, Biogen’s peers Roche and Eli Lilly are rallying behind the company’s troubled Alzheimer’s disease therapy, Aduhelm, in an effort to ch...

Humanity’s drugs have polluted rivers across the entire world and pose “a global threat to environmental and human health”, according to the most comprehensive study to date. ...

Researchers at the University of Toronto have identified hundreds of new proteins that could play a role in cystic fibrosis, and which may shed light on why some patients respond better than others...

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron varian...

Azurity Pharmaceuticals’ Fleqsuvy (baclofen oral suspension, 5 mg/mL) has won FDA approval for treating spasticity caused by multiple sclerosis (MS), spinal cord injuries or other spinal cord dis...